US · Healthcare · Biotechnology
EPS came in at -0.75 against a street estimate of -0.66 — a miss of 13.6%.
Analysts rate Immunovant Inc a strong buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $48.88.
CONFIDENT Roivant executing on 2026 roadmap: brexpiprazole DM launch imminent (priority review), Phase III cutaneous sarcoidosis underway, PH-ILD and NIU data expected H2. Strong cash position (~$4B pre-Moderna settlement), 1402 Graves data coming 2027. Q1 FY2026 No geographic segment breakdown provided. Analysts pressed on launch pace, clinical trial risks (placebo variability, JAK safety perception), and lack of analogs. Gline emphasized 'slow and steady' multi-indication strategy, noted patient unmet need exceeds competitive concerns, and deferred specific timing/metric guidance. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 8.21% |
| Deep Track Capital, LP | 4.52% |
| BlackRock Inc | 3.18% |
| Baker Bros Advisors LP | 2.64% |
| State Street Corp | 2.20% |
| TCG Crossover Management, LLC | 2.16% |
| Morgan Stanley - Brokerage Accounts | 1.88% |
| Vanguard Portfolio Management, LLC | 1.79% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 FY2027 IMMUNOVANT, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held September 2, 2026 with 198,373,370 shares represented (96% of entitled vo | 2026-09-03 |
| Quarterly report · Q1 FY2027 IMMUNOVANT, INC. – Q1 2026 (ENDED JUNE 30, 2026) SUMMARY HEADLINE NUMBERS • Cash position: $797.8 million as of June 30, 2026 (down from $902.1 mill | 2026-08-06 |
| Results announced · Q2 FY2027 IMMUNOVANT, INC. - Q1 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $797.8 million as of June 30, 2026, providing runway to potential c | 2026-08-06 |
| Proxy statement · Q2 FY2027 IMMUNOVANT, INC. – 2026 ANNUAL MEETING PROXY STATEMENT SUMMARY HEADLINE NUMBERS • Outstanding shares as of record date (July 8, 2026): 206,402,338 s | 2026-07-22 |
| Annual report FY2026 IMMUNOVANT, INC. — FORM 10-K SUMMARY (FISCAL YEAR ENDED MARCH 31, 2026) HEADLINE NUMBERS • Market capitalization (as of September 30, 2025): $1,252. | 2026-05-20 |
| Results announced · Q1 FY2027 IMMUNOVANT, INC. — FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and cash equivalents: $902.1 million as of March 31, 2026 • Common | 2026-05-20 |
| Quarterly report · Q3 FY2026 IMMUNOVANT, INC. – Q3 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $994.5 million as of December 31, 2025 (up from $714.0 million on Mar | 2026-02-06 |
| Results announced · Q4 FY2026 IMMUNOVANT, INC. – FINANCIAL SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $994.5 million as of December 31, 2025 (up from $714.0 m | 2026-02-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immunovant Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.